journal
https://read.qxmd.com/read/38768417/assessing-patterns-of-cgm-use-and-metrics-of-glycemic-control-in-t1d-and-t2d-patients-in-the-veterans-healthcare-system-integrating-cgm-device-data-with-ehr-data
#1
JOURNAL ARTICLE
Tomoki Okuno, Sharon Macwan, Donald Miller, Gregory Norman, Peter Reaven, Jin Zhou
OBJECTIVE: To integrate long-term daily continuous glucose monitoring (CGM) device data with electronic health records (EHR) for type 1 and type 2 diabetes patients in the Veterans Affairs Healthcare System to assess real-world patterns of CGM use and the reliability of EHR-based CGM information. RESEARCH DESIGN AND METHODS: This observational study used Dexcom CGM device data linked with EHR (from 2015-2020) for a large national cohort of diabetes patients. We tracked the initiation and consistency of CGM use, assessed concordance of CGM use and measures of glucose control between CGM device data and EHR records, and examined results by age, ethnicity, and diabetes type...
May 20, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38768416/continuous-glucose-monitoring-and-recreational-scuba-diving-in-type-1-diabetes-head-to-head-comparison-between-free-style-libre-3-and-dexcom-g7-performance
#2
JOURNAL ARTICLE
Elena Gamarra, Giovanni Careddu, Andrea Fazi, Valentina Turra, Ambra Morelli, Chiara Camponovo, Pierpaolo Trimboli
Background Scuba diving was previously excluded because of hypoglycemic risks for type 1 diabetic patients (T1DM). Specific eligibility criteria and a safety protocol have been defined, while continuous glucose monitoring (CGM) systems have enhanced diabetes management. This study aims to assess the feasibility and accuracy of CGM Dexcom G7 (DG7) and Free Style Libre 3 (FSL3) in a setting of repetitive scuba diving in T1DM, exploring the possibility of non-adjunctive use. Material and methods The study was conducted during an event of Diabete Sommerso® association in November 2023...
May 20, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38758213/expert-panel-recommendations-for-a-standardized-ambulatory-glucose-profile-report-for-connected-insulin-pens
#3
JOURNAL ARTICLE
Gregg D Simonson, Amy Criego, Tadej Battelino, Anders L Carlson, Pratik Choudhary, Sylvia Franc, Dana Gershenoff, George Grunberger, Irl B Hirsch, Diana Isaacs, Mary Johnson, David Kerr, Davida Kruger, Chantal Mathieu, Thomas Martens, Revital Nimri, Sean Oser, Anne Peters, Ruth S Weinstock, Eugene E Wright, Carol H Wysham, Richard M Bergenstal
BACKGROUND: Connected insulin pens capture data on insulin dosing/timing and can integrate with continuous glucose monitoring (CGM) devices with essential insulin and glucose metrics into a single platform. Standardization of connected insulin pen reports is desirable to enhance clinical utility with a single report. METHODS: An international expert panel was convened to develop a standardized connected insulin pen report incorporating insulin and glucose metrics into a single, clinically useful report...
May 17, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38758212/psychometric-properties-of-the-automated-insulin-delivery-benefits-and-burdens-scale-aid-bbs-for-adults-with-type-1-diabetes
#4
JOURNAL ARTICLE
Jenna B Shapiro, Anthony T Vesco, Michael S Carroll, Jill Weissberg-Benchell
OBJECTIVE: To evaluate the psychometric properties of a patient-reported outcome measure, The Automated Insulin Delivery - Benefits and Burdens Scale (AID-BBS), which was designed to assess benefits and burdens of AID use in adults with type 1 diabetes (T1D). The measure was hypothesized to have validity, reliability, and clinical utility for predicting likelihood of continued use of an AID system. RESEARCH DESIGN AND METHODS: 217 adults with T1D (ages 18 to 82 years) who were enrolled in an AID system research trial completed AID-BBS items at study midpoint (6 weeks) and at the end of the trial (13 weeks)...
May 17, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38758211/performance-of-subcutaneous-continuous-glucose-monitoring-in-adult-critically-ill-patients-receiving-vasopressor-therapy
#5
JOURNAL ARTICLE
Ola Friman, Navid Soltani, Marcus Lind, Pia Zetterqvist, Anca Balintescu, Anders Perner, Anders Oldner, Olav Rooyackers, Johan Mårtensson
Background Subcutaneous continuous glucose monitoring (CGM) may facilitate glucose control in the ICU. We aimed to assess the accuracy of CGM (Dexcom G6) against arterial blood glucose (ABG) in adult critically ill patients receiving intravenous insulin infusion and vasopressor therapy. We also aimed to assess feasibility and tolerability of CGM in this setting. Methods We included ICU patients receiving mechanical ventilation, insulin, and vasopressor therapy. Numerical accuracy was assessed by the mean absolute relative difference (MARD), overall, across arterial glucose strata, over different noradrenaline equivalent infusion rates, and over time since CGM start...
May 17, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38758194/real-life-achievements-of-minimed%C3%A2-780g-advanced-closed-loop-system-in-youth-with-type-1-diabetes-awesome-study-group-multi-center-prospective-trial
#6
JOURNAL ARTICLE
Noah Gruber, Avigail Wittenberg, Avivit Brener, Shirli Abiri, Kineret Mazor-Aronovitch, Michal Yackobovitch-Gavan, Shay Averbuch, Tal Ben-Ari, Noah Levek, Neriya Levran, Zohar Landau, Marianna Rachmiel, Orit Pinhas-Hamiel, Yael Lebenthal
BACKGROUND: We assessed real-life glycemic outcomes and predictors of composite measures of optimal glycemic control in children and adolescents with type 1 diabetes (T1D) during their initial 12 months of the MiniMed™ 780G use. METHODS: This prospective observational multicenter study collected demographic, clinical, and two-week 780G system data at five timepoints. Optimal glycemic control was defined as a composite glycemic control (CGC) score requiring the attainment of four recommended continuous glucose monitoring (CGM) targets, as well as the glycemia risk index (GRI) of hypoglycemia and hyperglycemia and composite CGM index (COGI)...
May 17, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38696672/multicenter-evaluation-of-ultra-rapid-lispro-urli-insulin-with-control-iq-technology-in-adults-adolescents-and-children-with-type-1-diabetes
#7
JOURNAL ARTICLE
Carol Levy, Ryan Bailey, Lori Mb Laffel, Gregory P Forlenza, Linda A DiMeglio, Michael S Hughes, Sue Brown, Grazia Aleppo, Anuj Bhargava, Viral Shah, Mark A Clements, Mark S Kipnes, Brittany Bruggeman, Mark Daniels, Henry Rodriguez, Peter Calhoun, John Lum, Ravid Sasson-Katchalski, Jordan E Pinsker, Robyn Pollom, Roy W Beck
OBJECTIVE: To evaluate the safety and explore the efficacy of use of ultra-rapid lispro (URLi, Lyumjev) insulin in the Tandem t:slim X2 insulin pump with Control-IQ 1.5 technology in children, teens and adults living with type 1 diabetes (T1D). METHODS: At 14 U.S. diabetes centers, youth and adults with T1D completed a 16-day lead-in period using lispro in a t:slim X2 insulin pump with Control-IQ 1.5 technology followed by a 13-week period in which URLi insulin was used in the pump...
May 2, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38662427/mitigating-severe-hypoglycemia-in-users-of-advanced-diabetes-technologies-impaired-awareness-of-hypoglycemia-and-unhelpful-hypoglycemia-beliefs-as-targets-for-interventions
#8
JOURNAL ARTICLE
Yu Kuei Lin, Wen Ye, Helen Rogers, Augustin Brooks, Elena Toschi, Dulmini Kariyawasam, Simon Heller, Nicole de Zoysa, Stephanie A Amiel
Objective: A subgroup analysis of the Hypoglycemia Awareness Restoration Programme for people with type 1 diabetes and problematic hypoglycemia persisting despite optimized care (HARPdoc) trial was conducted to explore the impact of Blood Glucose Awareness Training (BGAT, a hypoglycemia awareness training program) and the HARPdoc (a psychoeducation addressing unhelpful hypoglycemia beliefs) in reducing severe hypoglycemia (SH) in individuals using advanced diabetes technologies (ADTs). Methods: Data from trial participants who utilized ADTs, including continuous glucose monitors or automated insulin delivery systems, were extracted...
April 29, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38669475/predicting-hypoglycemia-and-hyperglycemia-risk-during-and-after-activity-for-adolescents-with-type-1-diabetes
#9
JOURNAL ARTICLE
Simon Bergford, Michael C Riddell, Robin Gal, Susana R Patton, Mark A Clements, Jennifer L Sherr, Peter Calhoun
OBJECTIVE: To predict hypoglycemia and hyperglycemia risk during and after activity for adolescents with type 1 diabetes (T1D) using real-world data from the Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) study. METHODS: Adolescents with T1D (n=225; [mean±SD] age=14±2 years; HbA1c=7.1±1.3%; T1D duration=5±4 years; 56% using hybrid closed loop), wearing continuous glucose monitors (CGM), logged 3,738 total activities over 10 days. Repeated Measures Random Forest (RMRF) and Repeated Measures Logistic Regression (RMLR) models were used to predict a composite risk of hypoglycemia (<70 mg/dL) and hyperglycemia (>250 mg/dL) within two hours after starting exercise...
April 26, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38669474/initiating-glp-1-therapy-in-combination-with-freestyle-libre-provides-greater-benefit-compared-to-glp-1-therapy-alone
#10
JOURNAL ARTICLE
Eugene E Wright, Gregory J Roberts, Joyce S Chuang, Yelena Nabutovsky, Naunihal Virdi, Eden Miller
BACKGROUND AND AIM: Glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy provides glycemic benefits to individuals with type 2 diabetes (T2D). However, the effects of GLP-1 RA therapy in combination with FreeStyle Libre systems (FSL) are unknown. This study aimed to compare changes in HbA1c between people acquiring GLP-1 with FSL (GLP-1+FSL) vs. GLP-1 without FSL (GLP-1). METHODS: This real-world study utilized Optum's de-identified Market Clarity Data, a linked electronic health records (EHR)-claims database and included adults with T2D and HbA1c ≥8% who acquired their first GLP-1 RA medication between 2018-2022...
April 26, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38669473/contemporary-management-of-obesity-a-comparison-of-bariatric-metabolic-surgery-and-novel-incretin-mimetic-drugs
#11
JOURNAL ARTICLE
Abhayjit Singh, Steven E Nissen
The global prevalence of obesity has risen sharply during the past half-century, reaching pandemic proportions and creating a public health crisis. Obesity is a recognized risk factor for the development of diabetes, atherosclerosis, hypertension, hepatic steatosis, and many other cardiometabolic disorders with significant resultant morbidity and mortality. Though treatment of obesity can prevent or slow the progression of these aforementioned illnesses, efforts to help patients achieve reliable and sustainable weight loss have had limited success...
April 26, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38669472/point-counterpoint-the-need-for-do-it-yourself-diy-open-source-os-aid-systems-in-type-1-diabetes-management
#12
JOURNAL ARTICLE
Gregory P Forlenza, Ideen Tabatabai, Dana Lewis
In the last decade, technology developed by people with diabetes and their loved ones has added to the options for diabetes management. One such example is that of automated insulin delivery (AID) algorithms, which were created and shared as open source by people living with type 1 diabetes (T1D) years before commercial systems were first available. Now, numerous options for commercial systems exist in some countries, yet tens of thousands of people with diabetes are still choosing Open-Source AID (OS-AID), previously called "do-it-yourself" (DIY) systems, which are non-commercial versions of these open-source AID systems...
April 26, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38662426/validation-of-the-uva-simulation-replay-methodology-using-clinical-data-reproducing-a-randomized-clinical-trial
#13
JOURNAL ARTICLE
María F Villa-Tamayo, Patricio Colmegna, Marc D Breton
BACKGROUND: Computer simulators of human metabolism are powerful tools to design and validate new diabetes treatments. However, these platforms are often limited in the diversity of behaviors and glycemic conditions they can reproduce. Replay methodologies leverage field-collected data to create ad-hoc simulation environments representative of real-life conditions. After formal validations of our method in prior publications, we demonstrate its capacity to reproduce a recent clinical trial...
April 25, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38662425/adaptive-bio-behavioral-control-a-pilot-analysis-of-human-machine-co-adaptation-in-type-1-diabetes
#14
JOURNAL ARTICLE
Patricio Colmegna, Ryan McFadden, Chiara Fabris, Benjamin Lobo, Ralf Nass, Mary Clancy-Oliveri, Sue A Brown, Boris P Kovatchev
BACKGROUND: While it is well recognized that an automated insulin delivery (AID) algorithm should adapt to changes in physiology, it is less understood that the individual would also have to adapt to the AID system. The adaptive bio-behavioral control (ABC) method presented here attempts to compensate for this deficiency by including AID into an information cloud-based ecosystem. METHODS: The Web Information Tool (WIT) implements the ABC concept via: (1) A Physiological Adaptation Module (PAM) that tracks metabolic changes and adapts AID parameters accordingly, and (2) a Behavioral Adaptation Module (BAM) that provides information feedback...
April 25, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38568138/contrasting-glycemic-outcomes-in-young-people-with-diabetic-ketoacidosis-at-onset-of-type-1-diabetes
#15
LETTER
Rama Lakshman, Mazin Najami, Roman Hovorka, Charlotte K Boughton
No abstract text is available yet for this article.
April 16, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38621172/progression-from-prediabetes-to-diabetes-in-a-diverse-us-population-a-machine-learning-model
#16
JOURNAL ARTICLE
Joseph Aoki, Omar Khalid, Cihan Kaya, Zoltan Nagymanyoki, Jerry Hussong, Mohamed Salama
Objective To date, there are no widely implemented machine learning (ML) models that predict progression from prediabetes to diabetes. Addressing this knowledge gap would aid in identifying at-risk patients within this heterogeneous population who may benefit from targeted treatment and management in order to preserve glucose metabolism and prevent adverse outcomes. The objective of this study was to utilize readily available laboratory data to train and test the performance of ML-based predictive risk models for progression from prediabetes to diabetes...
April 15, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38502158/are-new-ultra-rapid-acting-insulins-associated-with-improved-glycemic-control-and-reduced-hypoglycemia-in-comparison-to-conventional-rapid-acting-insulins-for-individuals-with-type-1-and-type-2-diabetes-a-systematic-review-and-meta-analysis
#17
JOURNAL ARTICLE
Rocío Villar-Taibo, Alba Galdón Sanz-Pastor, Elsa Fernández-Rubio, David Barajas Galindo, Andreu Simó Servat, Francisco Javier Ampudia-Blasco
Introduction: This study aimed to compare efficacy and safety of ultra-rapid-acting insulin analogs (URAIs; faster aspart [FAsp], ultra-rapid lispro [URLi], and technosphere insulin [TI]) with rapid-acting insulin analogs (RAI) in individuals with type 1 (T1D) or type 2 diabetes (T2D). Methods: Searching for randomized control trial comparing the effects of URAI versus RAI that lasted at least 12 weeks, we initially selected 15 studies for analysis. Three studies involving TI were excluded due to a high degree of heterogeneity...
April 15, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38512385/associations-between-hypoglycemia-awareness-status-and-symptoms-of-hypoglycemia-among-adults-with-type-1-or-insulin-treated-type-2-diabetes-using-the-hypo-metrics-smartphone-application
#18
JOURNAL ARTICLE
Gilberte Martine-Edith, Natalie Zaremba, Patrick Divilly, Uffe Søholm, Melanie Broadley, Petra Martina Baumann, Zeinab Mahmoudi, Mikel Gomes, Namam Ali, Evertine J Abbink, Bastiaan de Galan, Julie Brøsen, Ulrik Pedersen-Bjergaard, Allan A Vaag, Rory J McCrimmon, Eric Renard, Simon Heller, Mark Evans, Monika Cigler, Julia K Mader, Stephanie A Amiel, Jane Speight, Frans Pouwer, Pratik Choudhary
Introduction: This study examined associations between hypoglycemia awareness status and hypoglycemia symptoms reported in real-time using the novel Hypoglycaemia-MEasurement, ThResholds and ImpaCtS (Hypo-METRICS) smartphone application (app) among adults with insulin-treated type 1 (T1D) or type 2 diabetes (T2D). Methods: Adults who experienced at least one hypoglycemic episode in the previous 3 months were recruited to the Hypo-METRICS study. They prospectively reported hypoglycemia episodes using the app for 10 weeks...
April 12, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38512387/continuous-glucose-monitoring-derived-glucometrics-in-adults-with-type-1-diabetes-when-switching-basal-insulins
#19
JOURNAL ARTICLE
Robbe De Groote, Eveline Lefever, Sara Charleer, Phebe Donné, Christophe De Block, Chantal Mathieu, Pieter Gillard
Context: Limited evidence is available on the real-world effect of insulin degludec (IDeg) in type 1 diabetes (T1D), using continuous glucose monitoring (CGM)-derived metrics. Objective: To assess the real-world effect of switching to IDeg from other long-acting insulins on time in ranges (TIRs) measured by CGM, metabolic control, and insulin dose for people with T1D. Design: This retrospective multicenter study encompassed five time points during a 12-month pre-switch of IDeg and a 12-month follow-up period...
April 9, 2024: Diabetes Technology & Therapeutics
https://read.qxmd.com/read/38512386/response-to-minimed-780g-system-outperforms-other-automated-insulin-systems-due-to-algorithm-design-not-bias-response-to-inaccurate-allegations
#20
LETTER
Gregory P Forlenza, Jennifer L Sherr
No abstract text is available yet for this article.
April 5, 2024: Diabetes Technology & Therapeutics
journal
journal
34712
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.